We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

6 hedge funds and large institutions have $14.2M invested in Avalo Therapeutics in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

35,797% more capital inflows, than outflows

Capital inflows: $9.38M | Capital outflows: $26.1K

48.08% more ownership

Funds ownership: 15.89% → 63.97% (+48%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

33% less funds holding

Funds holding: 9 → 6 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
6
Holders Change
-3
Holders Change %
-33.33%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
+$9.38M

Top Sellers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
-$14K
2
Citadel Advisors
Citadel Advisors
Florida
-$10K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$2.14K

AVTX Hedge Fund Activity: Q3 2017 in Review

6 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2017, worth a combined $14.2M — up 498% from $2.37M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of AVTX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Armistice Capital, adding an estimated $9.38M. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $14K sold.

  • 6 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2017, down from 9 in Q2 2017.
  • Funds reported $14.2M of Avalo Therapeutics stock for Q3 2017, up 498% quarter-over-quarter.
  • 0 funds opened new Avalo Therapeutics positions in Q3 2017 and 2 closed out, a net change of -2 holders.
  • The largest Avalo Therapeutics buyer in Q3 2017 was Armistice Capital, an estimated $9.38M added.
  • The largest Avalo Therapeutics seller in Q3 2017 was Bank of New York Mellon, an estimated $14K sold.

Based on aggregated 13F filings for Q3 2017.